Skip to content Skip to sidebar Skip to footer
Subscribe Now
PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate Cancer Shots: The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…
February 9, 20220Comments

Read more

Viewpoints_Philip M. Brown
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM

In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque Psoriasis Shots: The P-III (PSOARING 1 & 2) trials evaluate the efficacy and safety of tapinarof (1%, qd) vs vehicle-controlled cream in a ratio (2:1) in 1025 patients aged…
February 8, 20220Comments

Read more

EXCLUSIVE

Exclusive Interview with PharmaShots: Moshe Safran of RSIP Vision Share Insight on the 3D Reconstruction Technology

In an interview with PharmaShots, Moshe Safran, CEO at RSIP Vision shared his views on the new coronary module in the complete 3D reconstruction of the coronary vasculature during angiography Shots: The company reported the 3D reconstruction technology that focused on AI to generate 3D models of patient anatomy from 2D images. The purpose of the technology is to create precise,…
February 7, 20220Comments

Read more

Viewpoints_Laura Dix
VIEWPOINTS

PharmaShots Interview: Accenture Life Sciences’ Laura Dix Shares Insights on the New Rules of Engagement to Provide HCPs New Interactions

In an interview with PharmaShots, Laura Dix, a Managing Director in Accenture’s Life Sciences Strategy and Consulting practice shares her views on the new research & provides more useful, data-driven information to HCPs  Shots: The company unveiled new research, titled The “New” Rules of Engagement & which have increased their relevance during COVID-19 through more valuable and meaningful interactions with…
February 2, 20220Comments

Read more

Viewpoints_Laurent Levy
VIEWPOINTS

PharmaShots Interview: Nanobiotix’s Laurent Levy Shares Insights on the P-III (NANORAY-312) Study of NBTXR3 for the Treatment of Head and Neck Squamous Cell Carcinoma

In an interview with PharmaShots, Laurent Levy, Co-Founder & CEO at Nanobiotix shares his views on the first patient enrollment of NBTXR3 in P-III (NANORAY-312) study for the treatment of head and neck squamous cell carcinoma Shots: The first patient has been enrolled in P-III (NANORAY-312) study to evaluate the efficacy & safety of NBTXR3 with/out cetuximab vs radiotherapy with/out cetuximab…
January 31, 20220Comments

Read more

Spotlight Interview_Michael Sassano
SPOTLIGHT

Spotlight Interview with Michael Sassano, CEO and Chairman of the Board for Somai Pharmaceuticals

On February 01, 2022, PharmaShots will present the second interview in its new interview section, “Spotlight- Company of the Month’’. Company of the month is our new exclusive feature under which we are interviewing the key leaders of the start-ups that are providing fierce solutions. We pick one company every month and interview them about…
January 27, 20220Comments

Read more

Viewpoints_Ilse Eder
VIEWPOINTS

PharmaShots Interview: E&E CRO Consulting’s Ilse Eder Shares Insights on the Trends of Clinical Research & New Healthcare Technologies

In an interview with PharmaShots, Ilse Eder, CEO at E&E CRO Consulting shares her views on the breakthrough healthcare technologies to improve patient outcomes Shots: Principal Technologies is an investor in the MedTech space. Its first investment is an 80% stake in E&E which is focused on helping companies earn international distribution permits via clinical studies  Principal Technologies focuses on identifying…
January 25, 20220Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]